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Abstract
Background: Dengue is the most important vector-borne viral infection of man, with approximately 2 billion
people living in areas at risk. Infection results in a range of manifestations from asymptomatic infection through to
life-threatening shock and haemorrhage. One of the hallmarks of severe dengue is vascular endothelial disruption.
There is currently no specific therapy and clinical management is limited to supportive care. Statins are a class of
drug initially developed for lipid lowering. There has been considerable recent interest in their effects beyond lipid
lowering. These include anti-inflammatory effects at the endothelium. In addition, it is possible that lovastatin may
have an anti-viral effect against dengue. Observational data suggest that the use of statins may improve outcomes
for such conditions as sepsis and pneumonia. This paper describes the protocol for a randomised controlled trial
investigating a short course of lovastatin therapy in adult patients with dengue.
Methods/design: A randomised, double-blind, placebo-controlled trial will investigate the effects of lovastatin
therapy in the treatment of dengue. The trial will be conducted in two phases with an escalation of dose between
phases if an interim safety review is satisfactory. This is an exploratory study focusing on safety and there are no
data on which to base a sample size calculation. A target sample size of 300 patients in the second phase, enrolled
over two dengue seasons, was chosen based on clinical judgement and feasibility considerations. In a previous
randomised trial in dengue, about 10% and 30% of patients experienced at least one serious adverse event or
adverse event, respectively. With 300 patients, we will have 80% power to detect an increase of 12% (from 10% to
22%) or 16% (from 30% to 46%) in the frequency of adverse events. Furthermore, this sample size ensures some
power to explore the efficacy of statins.
Discussion: The development of a dengue therapeutic that can attenuate disease would be an enormous advance
in global health. The favourable effects of statins on the endothelium, their good safety profile and their low cost
make lovastatin an attractive therapeutic candidate.
Trial registration: International Standard Randomised Controlled Trial Number ISRCTN03147572
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Background
Dengue is the most common and important vector-
borne viral infection of man, with at least 2 billion
people living in areas of risk [1]. Clinical dengue varies
from asymptomatic infection to severe disease charac-
terised by shock and haemorrhage. There are currently
no specific therapeutic agents and disease management
is limited to careful fluid management [2,3].
Statins
Statins are inhibitors of 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase. They were first
used clinically in the late 1980s and quickly became
established as an effective drug for both lipid lowering
and mortality reduction in cardiovascular disease [4].
They are currently one of the most prescribed classes of
drugs globally. Statins have an excellent safety profile
[5]. The most common adverse effects are rises in the
level of liver transaminases and myopathy. These effects
are rare and appear to be dose-related [5,6]. More recent
research has demonstrated that statins have additional
beneficial effects. These pleiotropic effects include the
restoration or improvement of endothelial cell function,
an increased production of nitric oxide, and a reduction
in the release of cytokines and acute phase proteins.
These effects lead to a reduction of inflammation within
the vessel wall [7,8]. Observational studies suggest that
statin therapy may result in improved outcomes for a di-
verse range of conditions, including sepsis and pneumo-
nia [9-13]. In addition, there are a number of on-going
randomised clinical trials to assess the therapeutic effi-
cacy of statins in sepsis and acute lung injury
(NCT00528580, NCT00676897, NCT00979121).
Statins and dengue
One of the major features of both dengue and sepsis is
widespread vascular endothelial disruption resulting, in
part, from exposure to inflammatory mediators [14-16].
This suggests that in view of their pleiotropic effects, it
is plausible that statins may favourably augment the
pathophysiological mechanisms of these two conditions.
A study in healthy volunteers showed that the
endotoxin-induced inflammatory response was sup-
pressed in those receiving a statin at a high dose (sim-
vastatin 80 mg), perhaps explaining the beneficial effect
observed in sepsis [8,17]. Furthermore, in vitro work has
demonstrated that lovastatin may have an anti-viral ef-
fect in dengue by reducing virion assembly [18,19].
Choice of study drug
We have chosen lovastatin as the study drug for both
scientific and pragmatic reasons. In light of the US Food
and Drug Administration’s safety recommendations
about the risks of muscle toxicity with simvastatin, there
were concerns from the regulatory authorities in Vietnam
about the safety of using this agent in dengue. An additional
reason for our choice was the dengue anti-viral effect
observed with lovastatin in in vitro experiments [18]. As
this effect may also be observed in vitro, we believe it is
rational to test the drug used in the original work. Further-
more, lovastatin is commonly prescribed and available in
Vietnam as a generic and will therefore be immediately
available to patients if there is a positive result from the
trial.
Aims of the trial
Typically, severe vascular leakage and shock occur
around the fifth day of illness in patients with dengue
[20]. It is possible that initiation of statin therapy early
in the course of the illness may prevent or favourably
modulate these effects. As the proportion of patients
who develop shock or other complications after presen-
tation to hospital is low (approximately 5%), a large trial
would be required to demonstrate a clinical benefit
[2,21]. However, this study presents an opportunity to
assess formally the safety of using statins in the treat-
ment of this disease. In addition, such a study will also
provide an opportunity to investigate the effect of statin
usage on the immune response during dengue infection
and to generate preliminary data for planning a Phase III
trial in the future.
Although there is extensive experience of using statins
as a lipid-lowering agent, and an increase in the amount
of observational data from their use in critically ill
patients, this will be the first study looking at the use of
statins in dengue. We propose to investigate the effect of
lovastatin for 5 days in adult dengue patients presenting
in the first 72 hours of illness. The rational of a 5-day
treatment course is to cover the transient ‘critical’ phase
of infection when complications arise, which typically
occurs around the fifth day of illness [3]. Our proposed
treatment course will start on the second or third day of
illness and continue to the seventh or eighth day of
illness, which is into the recovery phase. As this is the
first study investigating statin therapy in dengue with a
particular focus on safety, we propose a dose-escalation
study, investigating 40 mg lovastatin versus placebo with
a safety review after recruitment of the first 30 patients.
If this review is satisfactory, we will increase the lovasta-
tin dose to 80 mg and conduct a further safety review
after the next 30 patients.
Methods/design
Design
This study is a randomised, placebo-controlled, double-
blind trial investigating lovastatin therapy in Vietnamese
adults with dengue infection. The trial will be conducted
in two phases, with an escalation of dose between phases
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if the results of an interim data review show no safety
concerns within the first cohort of patients treated with
the lower dose.
Patients will be followed for clinical and laboratory
endpoints in hospital until study day 6 (or daily as out-
patients from discharge to day 6) and reviewed at an
outpatient visit on day 28.
Inclusion and exclusion criteria
All patients aged 18 or more presenting to the Hospital
of Tropical Diseases, Ho Chi Minh City with a clinical
suspicion of dengue, less than 72 hours of fever and a
positive rapid test for dengue non-structural protein 1
(NS1) will be eligible for recruitment into the study. Ex-
clusion criteria are: signs or symptoms suggestive of an-
other acute infectious disease, alanine transaminase
levels greater than 150 U/l, creatine kinase levels greater
than 1000 U/l, liver cirrhosis, myopathy, current or use
within past week of statins, pregnancy and lactation. In
addition, patients taking medications contraindicated for
use with statins, for example, isoniazid for treatment of
tuberculosis, will be excluded.
Primary endpoint
The primary endpoint of this study is an evaluation of
the safety and tolerability of lovastatin therapy in adult
patients with dengue. Comparing the rates of adverse
events between randomised treatment arms will assess
this.
Secondary endpoints
The secondary endpoints of this study are fever clear-
ance time (see definition), plasma viraemia (area under
the log-transformed viraemia curve from enrolment
until study day 6), platelet nadir between day 3 and 8 of
illness, maximum haematocrit between day 3 and 8 of
illness, percentage increase in haematocrit between day
3 and 8 of illness from baseline, maximum alanine trans-
aminase (ALT) and creatine kinase (CK) recorded be-
tween day 3 and 8 of illness, lowest oxygen saturation
recorded between day 3 and 8 of illness, number of
patients in each group requiring colloid, and disease
progression as defined by one or more of the following:
(a) admission to the ICU, (b) diagnosis of shock (see
definition), (c) diagnosis of severe bleeding (see defin-
ition), (d) development of encephalitis, (e) death. In
addition, quality of life scores obtained using a visual
analogue scale will be compared between treatment
groups. The times from enrolment to the first sample
with viraemia less than 1000 copies/ml and the first
negative NS1 antigenaemia sample will be compared be-
tween treatment groups.
Definitions
1. Fever clearance time is the time from enrolment to
the first time the temperature falls to <37.5°C and
remains below this level for 48 hours.
2. Shock: cardiovascular decompensation requiring fluid
resuscitation and considered to be due to plasma
leakage.
3. Severe bleeding is clinically severe if it results in
haemodynamic instability or requires fluid
resuscitation or a blood transfusion. Any bleeding
resulting in death and any intracranial bleed are
considered severe.
4. Baseline haematocrit: the haematocrit value obtained
at the day 28 follow-up visit, or (if the day 28 value is
missing) the expected age- and sex-matched
population value.
Randomization procedure
Randomization to either treatment arm will be in a 1:1
ratio. Randomization will be stratified according to the
ward of recruitment. A randomization list will be pre-
pared and maintained confidentially from study staff by
the clinical trials pharmacist. Block randomization using
variable block sizes will be used.
A chronological log of all enrolled patients will be
maintained. Each enrolled patient will be assigned the
next available sequential study code. The assigned num-
ber will correspond to a coded, sealed, pre-packaged bot-
tle containing six doses of either lovastatin or visually
matched placebo. Blinding will be maintained amongst
the attending physicians and nurses by ensuring that the
study drug and the placebo have an identical appearance.
In addition the administration schedule will be identical.
Enrolment
Patients presenting to the out-patients department or
in-patient wards with a clinical suspicion of dengue and
less than 72 hours of fever will be identified to study
staff. Study staff will approach these patients, check eli-
gibility criteria and confirm dengue by NS1 rapid test.
Eligible and consenting patients will have screening
blood tests sent and provided these are satisfactory will
be allotted the next consecutive study number and en-
rolled to the study.
Safety reviews
This trial will be conducted in two phases with an escal-
ation of dose if the results of an interim data review
show no safety concerns within the first cohort treated
with the lower dose. The dose will begin at 40 mg per
day in cohort 1 and may continue at 80 mg per day in
cohort 2. A DSMB (data and safety monitoring board)
review will take place when day 6 study data are
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available from the 30th patient enrolled in cohort 1. If
this review is satisfactory, the dose will be increased to
80 mg per day and recruitment into cohort 2 will com-
mence. Further DSMB reviews will take place when day
6 study data are available from the 30th and 100th
patients enrolled in cohort 2.
Treatment and drug dispensation
Patients will be assigned to one of two treatment arms:
 Active medicinal product: 40 mg (stage 1) or 80 mg
(stage 2) lovastatin once daily for 5 days.
 Placebo: visually matched placebo once daily for 5
days.
The first dose will be given as soon as practically pos-
sible after enrolment.
An unblinded study pharmacist will prepare study
drug bottles centrally and will distribute the bottles as
required. Drugs will be stored in accordance with the
manufacturers’ recommendations in a secure area.
Lovastatin and the placebo must be maintained below
25°C. All movements of study medication will be
recorded. Both individual subject and overall drug ac-
countability records will be kept up to date by the study
staff.
Data collection
Clinical evaluation
Patients will be followed by a study physician daily until
discharge, and all signs and symptoms recorded in the
case report form. An ultrasound scan will be performed
on day 6 of illness to detect signs of plasma leakage.
Clinical management decisions will remain in the hands
of the attending ward doctors. In the event that shock or
any other serious complication develops, the patient will
be transferred to the appropriate ICU. Details of all ad-
verse events will be recorded on specific forms, together
with an assessment as to whether the event is likely to
be related to any treatment received, and all serious
events will be reported promptly to the DSMB.
Quality of life will be measured by questionnaire and
visual analogue scale daily.
Patients who are fit to discharge on or after study day
3 may be followed as an outpatient until study day 6. All
patients will be asked for attend a follow-up visit for re-
view after 4 weeks.
Laboratory evaluation
Haematocrit, platelet and total cholesterol measure-
ments will be carried out daily or more frequently if
clinically indicated. These tests will be repeated at the
follow-up visit.
Renal and liver function tests, electrolytes and coagu-
lation profiles, will be carried out at enrolment, 48 hours
later, day 5 or 6 of illness and at the follow-up visit. If
the ALT measured 48 hours after enrolment is greater
than 250 U/l, the study drug will be discontinued. It
should, however, be noted that hepatic dysfunction
might be secondary to dengue infection and could be
positively affected by statin therapy.
Conventional serological and virological tests will be
used to confirm dengue infection and identify the infect-
ing serotype. Plasma samples collected at daily intervals
until discharge (and daily until day 6 if discharged before
day 6) will be assessed for viraemia levels, NS1 levels,
and concentrations of various pro- and anti-
inflammatory cytokines (TNF-α, IFN-γ, IL-6, IL-10).
DNA will be extracted from residual blood samples
and genotyped for genetic variants known to be asso-
ciated with severe dengue, for example, MICB and
PLCE1 [22].
Statistical considerations
Sample size
This is an exploratory study focusing primarily on safety
and there are no preliminary data regarding the effects
of statins in dengue on which to base a sample size cal-
culation. A target sample size of 300 patients in cohort
2, enrolled over two dengue seasons, was chosen based
on clinical judgement and feasibility considerations. In a
previous randomised trial in dengue, about 10% and 30%
of patients experienced at least one serious adverse event
or adverse event, respectively [23]. With 300 patients,
we will have 80% power to detect an increase of 12%
(from 10% to 22%) or 16% (from 30% to 46%) in the fre-
quency of adverse events. In addition, this sample size
ensures some power to explore the efficacy of statins.
Specifically, this study will have 80% power to detect an
increase in the rate of fever clearance by 40% due to sta-
tins. Based on simulations, we previously found that 30
patients give approximately 80% power to detect a 0.5
log10-copies/ml per day higher viraemia clearance, a
reasonable estimate of what an effective anti-viral might
achieve [24]. Thus, with 300 patients (a ten-fold higher
sample size), we expect to be able to detect a (hypothet-
ical) 0.16 log10-copies/ml per day higher viraemia clear-
ance due to statins.
Statistical analysis
The primary analysis population will include all patients
randomised to placebo from cohort 1 and all patients
(regardless of treatment assignment) from cohort 2
according to the intention-to-treat principle. Owing to
their low number, patients randomised to low-dose sta-
tins from cohort 1 will only be descriptively analysed.
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The proportion of patients with any adverse events,
any serious adverse events, or specific adverse events
will be summarised and compared between the treat-
ment arms based on Fisher’s exact test.
Pre-defined secondary endpoints will be compared be-
tween the two treatment arms based on linear regression
for continuous endpoints, logistic regression for binary
endpoints, and Cox regression for time-to-event end-
points. For laboratory markers, comparisons will be
adjusted for the pre-dose value of the respective marker
and the day of illness at enrolment; plasma viraemia and
NS1-endpoints will additionally be adjusted for dengue
serotype.
The clinical, virological and immunological findings
will also be correlated with MICB and PLCE1 genotype
using descriptive statistical methods.
A detailed statistical analysis plan will be finalised
prior to unblinding the study data base.
Ethical considerations
Ethical approval
This protocol and both the patient information sheet
and the consent form have been reviewed and approved
by the Institutional Review Board of the Hospital for
Tropical Diseases in Ho Chi Minh City, the Oxford
Tropical Research Ethics Committee and the Ethics Com-
mittee of the London School of Hygiene and Tropical
Medicine.
Informed consent and information sheet
All patients entering the study must give informed
consent.
Withdrawal from the trial
Each participant has the right to withdraw from the
study at any time. The reason for withdrawal will be
recorded in the case report form.
Confidentiality
Patients who enter the trial will be given a unique identi-
fication number. This number will be used on both la-
boratory specimens and case report forms. The study
wards and the research unit have the facilities to store
study information securely.
The role of the data and safety monitoring board (DSMB)
An independent DSMB will be set up consisting of a
biostatistician and senior clinical researchers with ex-
pertise in dengue and clinical trials. The DSMB will re-
view the protocol and agree to a data review schedule
and reporting requirements before the study com-
mences. All data reviewed by the DSMB will be in the
strictest confidence. A DSMB charter will outline its re-
sponsibilities and operation.
The DSMB will perform a safety review after day 6
data are available for the first 30 patients enrolled (Co-
hort 1: 40 mg lovastatin daily). This review will be based
on a report created by the DSMB statistician containing
unblinded summary tables of baseline demographics,
serious adverse effects, adverse effects and disease pro-
gressions, as well as viraemia curves. If no safety con-
cerns are identified, the lovastatin dose will be increased
to 80 mg daily and recruitment will commence in cohort
2. Enrolment will continue in cohort 1 while awaiting
the outcome of the DSMB review. Additional safety
reviews will take place after the day 6 data are available
for the 30th and 100th patients in cohort 2.
Discussion
Dengue remains a significant global public health chal-
lenge with costs to both the infected individual and the
struggling health systems of dengue-endemic countries.
At present, treatment is limited to supportive care. A
therapeutic that can attenuate disease and prevent pro-
gression to severe disease would represent a highly sig-
nificant advance with enormous benefits for both
patients and health systems. There is growing observa-
tional evidence from the critical care field to suggest that
statins may have a beneficial role in a number of condi-
tions, such as sepsis, acute lung injury and pneumonia.
Statins have beneficial pleiotropic effects, including sta-
bilizing and anti-inflammatory effects on the endothe-
lium. As endothelial dysfunction is so important in
dengue pathogenesis, stabilizing effects at this site may
prove to be clinically beneficial. In addition, statins have
an excellent safety profile and a low cost. In view of this,
we are optimistic about the potential benefit of lovasta-
tin in dengue.
Trial status
We expect that patients will start being recruited to this
trial in November 2012.
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